コンテンツへスキップ
Merck
  • Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.

Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer.

The Journal of clinical investigation (2018-01-13)
Peter J Chockley, Jun Chen, Guoan Chen, David G Beer, Theodore J Standiford, Venkateshwar G Keshamouni
要旨

During epithelial-mesenchymal transition (EMT) epithelial cancer cells transdifferentiate into highly motile, invasive, mesenchymal-like cells, giving rise to disseminating tumor cells. Few of these disseminated cells successfully metastasize. Immune cells and inflammation in the tumor microenvironment were shown to drive EMT, but few studies investigated the consequences of EMT for tumor immunosurveillance. In addition to initiating metastasis, we demonstrate that EMT confers increased susceptibility to natural killer (NK) cells and contributes, in part, to the inefficiency of the metastatic process. Depletion of NK cells allowed spontaneous metastasis without affecting primary tumor growth. EMT-induced modulation of E-cadherin and cell adhesion molecule 1 (CADM1) mediated increased susceptibility to NK cytotoxicity. Higher CADM1 expression correlates with improved patient survival in 2 lung and 1 breast adenocarcinoma patient cohorts and decreased metastasis. Our observations reveal a novel NK-mediated, metastasis-specific immunosurveillance in lung cancer and present a window of opportunity for preventing metastasis by boosting NK cell activity.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
抗マウスIgG (全分子)-ペルオキシダーゼ ウサギ宿主抗体, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
モノクロナール抗GAPDH−ペルオキシダーゼ マウス宿主抗体, clone GAPDH-71.1, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
モノクロナール抗ビメンチン マウス宿主抗体, clone VIM-13.2, ascites fluid
Sigma-Aldrich
抗SynCAM ウサギ宿主抗体, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
抗CADM1抗体, from rabbit, purified by affinity chromatography
Sigma-Aldrich
MISSION® esiRNA, targeting human CADM1